Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bjerrum (Aarhus, Denmark), J. Schmid (Aarhus, Denmark), T. Skjold (Aarhus, Denmark). Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.. 601

Member's Comments

No comment yet.

Related content which might interest you: Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018 Year: 2019 Real-world treatment patterns of mepolizumab therapy in Canada Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Efficacy of antifibrotics in chronic hypersensitivity pneumonitis. A 3 year real-life observational study Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Changing between anti-IL5 and anti-IL5 receptor treatments. A real-life study Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Unlicensed use of high-dose inhaled corticosteroids in the UK occurs principally with fluticasone - an observational study of 26359 patients Source: Eur Respir J 2004; 24: Suppl. 48, 501s Year: 2004 Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020 Year: 2021 Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007 The efficacy of the assistant use of short-acting β2 stimulant procaterol on the daily activity in COPD patients. Niigata multicenter study Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Study to evaluate clinical burden related with oral corticosteroids treatment of severe asthma in Spain (LEVANTE) Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Asthma control with inhaled corticosteroid therapy: A real-world observational study Source: Annual Congress 2010 - Management of airway disease Year: 2010 Oral corticosteroid (OCS)-sparing effect of tralokinumab in severe, uncontrolled asthma: the TROPOS study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018